SCHEDULE: Iroquois Capital Discloses 5.4% Stake in Bionano Genomics

Iroquois Capital Management and its principals, Richard Abbe and Kimberly Page, reported a combined 5.4% beneficial ownership in Bionano Genomics, Inc. common stock.

Summary

• Iroquois Capital Management LLC, Richard Abbe, and Kimberly Page (the "Reporting Persons") collectively reported beneficial ownership in Bionano Genomics, Inc. common stock.
• Richard Abbe beneficially owns 525,000 shares, representing 5.4% of the common stock outstanding.
• Iroquois Capital Management LLC and Kimberly Page each beneficially own 367,500 shares, representing 3.8% of the common stock outstanding.
• The reported percentages are based on 9,755,265 shares of common stock outstanding as of September 16, 2025, as indicated in the company's Prospectus (Registration No. 333-290187).
• The Reporting Persons also hold warrants exercisable for an aggregate of 1,050,000 shares of common stock, which are not included in the beneficial ownership calculation.
• These warrants are subject to "Beneficial Ownership Blockers," preventing their exercise if it would result in the holder owning more than 4.99% of the outstanding common stock, rendering them not currently exercisable.
• The filing certifies that the securities were acquired and are held for passive investment purposes, not to change or influence control of the issuer.

Sentiment

Score: 5

Explanation: Neutral, as this is a standard disclosure of passive beneficial ownership, not a performance report or strategic announcement.

Positives

• The disclosure of a significant institutional investor group (Iroquois Capital Management) holding a passive stake in Bionano Genomics may signal investor interest.

Negatives

• The beneficial ownership blockers on the warrants prevent the Reporting Persons from immediately increasing their stake beyond 4.99% through warrant exercise, which could limit their potential upside from these instruments.

Risks

• For the Reporting Persons, the "Beneficial Ownership Blockers" on the warrants mean they cannot exercise them to increase their stake beyond 4.99% of the outstanding common stock, limiting their ability to capitalize on potential future stock price appreciation through these specific instruments.

Future Outlook

This filing does not contain any forward-looking statements or guidance from Bionano Genomics, Inc. regarding its future performance or operations.

Industry Context

This is a standard disclosure of passive beneficial ownership by an investment firm and its principals, which is a routine event in the public markets. It does not provide specific insights into broader industry trends or competitive landscape for Bionano Genomics.

Stakeholder Impact

• Shareholders: Disclosure of a significant passive investor group holding a stake in the company.

Next Steps

• The Reporting Persons will file amendments to this Schedule 13G if there are material changes to their beneficial ownership or intent.

Key Dates

Recommendation

This Schedule 13G filing primarily discloses the beneficial ownership stake of Iroquois Capital Management and its principals in Bionano Genomics. It does not contain financial performance data, strategic updates, or forward-looking guidance from the company that would warrant a change in investment recommendation. The disclosed stake is passive, and the warrants held by the reporting persons are not currently exercisable due to beneficial ownership blockers, limiting their immediate impact on the company's share structure or control. Therefore, a 'hold' recommendation is appropriate as the filing itself does not present new fundamental information to alter an existing investment thesis.

Keywords

Bionano Genomics, Iroquois Capital Management, Richard Abbe, Kimberly Page, Schedule 13G, beneficial ownership, common stock, warrants, SEC filing, investment